Drug intelligence / Profile preview

BLI-1402

Development stage: Unknown
Lead developer: BioLite
Modality: Small Molecules

Overview

BLI-1402 is a small molecule drug candidate developed by BioLite. It is currently in the discovery phase and has not yet entered clinical trials. The primary indication under investigation for BLI-1402 is fatigue, but no detailed information about its mechanism of action, molecular target, or additional therapeutic areas has been disclosed publicly as of the latest updates. The drug remains in early-stage research and development[1][3][9].

Beyond the preview

Go deeper on BLI-1402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BLI-1402.

Explore the full profile